We are live on ! Find out more
ELGX

Endologix Inc
ELGX

Delisted

ELGX was delisted on the 15th of July, 2020.

99 hedge funds and large institutions have $56M invested in Endologix Inc in 2018 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 31 increasing their positions, 25 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 25

5% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 21

1% less funds holding

Funds holding: 10099 (-1)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

63% less capital invested

Capital invested by funds: $152M → $56M (-$95.9M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1K

Holders
99
Holders Change
-1
Holders Change %
-1%
% of All Funds
2.21%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
20
Increased
31
Reduced
25
Closed
21
Calls
Puts
$1K
Net Calls
-$1K
Net Calls Change
-$124K
Name Holding Trade Value Shares
Change
Change in
Stake
Charles Schwab
26
Charles Schwab
California
$384K +$130K +11,717 +28%
AQR Capital Management
27
AQR Capital Management
Connecticut
$356K +$553K +49,695 New
Wellington Management Group
28
Wellington Management Group
Massachusetts
$315K
Deutsche Bank
29
Deutsche Bank
Germany
$309K +$240K +21,571 +99%
BCM
30
Bridgeway Capital Management
Texas
$269K +$418K +37,500 New
JG
31
Jefferies Group
New York
$238K +$370K +33,255 New
Bank of New York Mellon
32
Bank of New York Mellon
New York
$237K -$29.6K -2,659 -7%
LOAMU
33
Lombard Odier Asset Management (USA)
New York
$233K -$418K -37,513 -54%
Renaissance Technologies
34
Renaissance Technologies
New York
$214K +$237K +21,267 +246%
AGM
35
Alpine Global Management
New York
$211K +$328K +29,433 New
Two Sigma Advisers
36
Two Sigma Advisers
New York
$178K +$123K +11,030 +79%
Goldman Sachs
37
Goldman Sachs
New York
$175K -$3.08K -277 -1%
KCM
38
Kennedy Capital Management
Missouri
$157K -$535 -48 -0.2%
SG Americas Securities
39
SG Americas Securities
New York
$155K +$241K +21,674 New
SIM
40
Spark Investment Management
New York
$134K +$60K +5,390 +40%
PPA
41
Parametric Portfolio Associates
Washington
$132K -$20.9K -1,872 -9%
Dimensional Fund Advisors
42
Dimensional Fund Advisors
Texas
$127K
Morgan Stanley
43
Morgan Stanley
New York
$114K +$18.3K +1,646 +11%
Wells Fargo
44
Wells Fargo
California
$110K +$4.51K +405 +3%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$104K +$20.7K +1,856 +15%
CS
46
Candriam SCA
Luxembourg
$100K -$89.1K -8,000 -36%
Marshall Wace
47
Marshall Wace
United Kingdom
$85K -$7.07K -635 -5%
Millennium Management
48
Millennium Management
New York
$82K -$745K -66,927 -85%
TI
49
Telemetry Investments
New York
$79K +$123K +11,000 New
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$77K +$34.2K +3,070 +40%

ELGX Hedge Fund Activity: Q4 2018 in Review

99 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Endologix Inc (ELGX) for Q4 2018, worth a combined $56M — down 63% from $152M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of ELGX and 20 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 31 added.

The largest buyer was JP Morgan Chase, adding an estimated $931K. The largest seller was PFM Health Sciences, exiting entirely with an estimated $14.2M sold.

  • 99 institutional investors held Endologix Inc (ELGX) as of Q4 2018, down from 100 in Q3 2018.
  • Funds reported $56M of Endologix Inc stock for Q4 2018, down 63% quarter-over-quarter.
  • 20 funds opened new Endologix Inc positions in Q4 2018 and 21 closed out, a net change of -1 holder.
  • The largest Endologix Inc buyer in Q4 2018 was JP Morgan Chase, an estimated $931K added.
  • The largest Endologix Inc seller in Q4 2018 was PFM Health Sciences, an estimated $14.2M sold.

Based on aggregated 13F filings for Q4 2018.